Precision Targeting GTPases in Cancer, Autoimmunity and Fibrosis Precision Targeting GTPases in Cancer, Autoimmunity
#14 of 55 therapeutics startups
▲ 1 since the last ranking
Ranked 6:02 AM PT · Thu, Nov 19
Listed
Precision Targeting GTPases in Cancer, Autoimmunity and Fibrosis Precision Targeting GTPases in Cancer, Autoimmunity and Fibrosis MBQ-167 Our lead compound, MBQ-167, is a first-in-class therapeutic which simultaneously inhibits both Rac and CDC42, removing pre-existing metastases. MBQ-167 is currently in its Phase-1 study. Prevention of Metastatic Growth and
If a fact is wrong, or you want the profile removed, tell us: we act on every request within 2 business days.